Hanmi Pharm Co Ltd Total Liabilities
Hanmi Pharm Co Ltd total liabilities. Based on the latest financial reports, Hanmi Pharm Co Ltd (128940) has total liabilities worth ₩694.79 Billion KRW (≈ $470.85 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Hanmi Pharm Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Hanmi Pharm Co Ltd (2010–2024)
Total liabilities of Hanmi Pharm Co Ltd from 2010 to 2024. This chart illustrates how Hanmi Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 128940 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Hanmi Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hanmi Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Science Applications International Corporation Common Stock
NYSE:SAIC
|
USA | $3.68 Billion |
|
Synnex Technology International Corp
TW:2347
|
Taiwan | NT$211.94 Billion |
|
Hongda
SHG:600331
|
China | CN¥587.78 Million |
|
Narayana Hrudayalaya Ltd.
NSE:NH
|
India | Rs-45.40 Billion |
|
Americold Realty Trust
NYSE:COLD
|
USA | $5.22 Billion |
|
Grupo Financiero Galicia S.A
F:GF4
|
Germany | €36.57 Trillion |
|
Envista Holdings Corp
NYSE:NVST
|
USA | $2.52K |
|
Global Health Limited
NSE:MEDANTA
|
India | Rs-39.84 Billion |
Liability Composition Analysis (2010–2024)
This chart breaks down Hanmi Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 128940 total assets.
Liquidity & Leverage Metrics
Hanmi Pharm Co Ltd Total Liabilities Ratios Explained
Hanmi Pharm Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hanmi Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hanmi Pharm Co Ltd (2010–2024)
The table below shows the annual total liabilities of Hanmi Pharm Co Ltd from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩780.09 Billion ≈ $528.66 Million |
-2.30% |
| 2023-12-31 | ₩798.46 Billion ≈ $541.10 Million |
-12.77% |
| 2022-12-31 | ₩915.36 Billion ≈ $620.33 Million |
-9.23% |
| 2021-12-31 | ₩1.01 Trillion ≈ $683.43 Million |
-3.97% |
| 2020-12-31 | ₩1.05 Trillion ≈ $711.66 Million |
-3.78% |
| 2019-12-31 | ₩1.09 Trillion ≈ $739.66 Million |
+21.01% |
| 2018-12-31 | ₩901.95 Billion ≈ $611.24 Million |
+3.85% |
| 2017-12-31 | ₩868.51 Billion ≈ $588.58 Million |
+0.70% |
| 2016-12-31 | ₩862.45 Billion ≈ $584.47 Million |
-11.80% |
| 2015-12-31 | ₩977.78 Billion ≈ $662.63 Million |
+120.18% |
| 2014-12-31 | ₩444.09 Billion ≈ $300.95 Million |
+6.25% |
| 2013-12-31 | ₩417.95 Billion ≈ $283.24 Million |
-1.95% |
| 2012-12-31 | ₩426.25 Billion ≈ $288.86 Million |
+4.08% |
| 2011-12-31 | ₩409.53 Billion ≈ $277.53 Million |
-3.03% |
| 2010-12-31 | ₩422.34 Billion ≈ $286.22 Million |
-- |
About Hanmi Pharm Co Ltd
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two activ… Read more